Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methacrylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.33 |
| ▸ | CRAT | P43155 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL540788 | 0.97 | CA4 (0.38) | CA4BBOX1MEN1CYP1A2HRH1 | |
| Methacrylic Acid SCHEMBL873040 | 0.95 | POLB (0.38) | CA4BBOX1MEN1CYP1A2HRH1 | |
| Methacrylic Acid SCHEMBL28377504 | 0.85 | BBOX1 (0.45) | CA4BBOX1CA1TDP1 | |
| Methacrylic Acid SCHEMBL4924752 | 0.85 | BBOX1 (0.45) | CA4BBOX1CYP2C19CA1TDP1 | |
| Methacrylic Acid SCHEMBL6553565 | 0.85 | BBOX1 (0.36) | BBOX1MEN1CYP1A2HRH1KMT2A | |
| Methacrylic Acid SCHEMBL17453351 | 0.83 | TDP1 (0.38) | CA4BBOX1CA1TDP1 | |
| Methacrylic Acid SCHEMBL20917781 | 0.82 | TSHR (0.38) | CYP2C19POLBBLMATMTDP1 | |
| Tetrylammonium SCHEMBL2347482 | 0.82 | TSHR (0.42) | CA4BBOX1CA1ATMTDP1 | |
| Methacrylic Acid SCHEMBL8154112 | 0.82 | ALDH1A1 (0.41) | BBOX1POLBBLMATMTDP1 | |
| Methacrylic Acid SCHEMBL4926692 | 0.81 | ACHE (0.38) | CA4BBOX1CYP2C19POLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912644-A | Amphiphilic sizing agent applicable to glass fiber/resin composite material | 宁波维创柔性电子技术有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119072297-A | Microcapsules and methods | 联合利华知识产权控股有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-113438939-A | Protein microcapsule and preparation method thereof | 国际香料和香精公司 | 2021-09-24 | — | — | CN | claimed |
| EP-1232190-B1 | WATER-IN-OIL POLYMER EMULSION AND METHOD FOR MAKING SAME | ARKEMA FRANCE (FR) | 2011-07-20 | — | — | EP | claimed |
| WO-2009063042-A1 | THICKENED REDUCING COMPOSITION | L'OREAL (FR) | 2009-05-22 | — | — | WO | claimed |
| EP-0940136-B1 | Reducing agent from a plurality of components and process for permanent hair waving using it | OREAL (FR) | 2004-10-13 | — | — | EP | claimed |
| EP-0930061-B1 | Oxidizing agent from a plurality of components and process for permanent hair waving using it | OREAL (FR) | 2004-02-25 | — | — | EP | claimed |
| US-6238658-B1 | THICKENING POLYMER BEING IN THE FORM OF AN AQUEOUS DISPERSION, AN OILY DISPERSION, OR AS A REVERSE EMULSION, WITH THE PROVISO THAT SAID THICKENING POLYMER IS NOT QUATERNARY HYDROXYETHYLCELLULOSE | L'OREAL S.A. (FR) | 2001-05-29 | — | — | US | claimed |
| US-6187302-B1 | THIOL-BEARING REDUCING AGENT IN AQUEOUS MEDIUM, AND AT LEAST ONE THICKENING POLYMER IN AQUEOUS MEDIUM, SAID THICKENING POLYMER BEING IN THE FORM OF AN AQUEOUS DISPERSION, AN OILY DISPERSION, OR A REVERSE EMULSION | L'OREAL S.A. (FR) | 2001-02-13 | — | — | US | claimed |
| EP-0635265-B1 | Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid | CT LAB FARM SRL (IT) | 2000-02-02 | — | — | EP | claimed |
| EP-0635265-A1 | Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid | LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) | 1995-01-25 | — | — | EP | claimed |
| US-12622853-B2 | Composition comprising a particular oxidation dye precursor and a particular amino silicone | L'OREAL (FR) | 2026-05-12 | — | — | US | disclosed |
| EP-4698156-A1 | RECONSTITUTABLE DRY POWDER FORMULATIONS AND METHODS OF USE THEREOF | Sanofi Pasteur Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12558301-B2 | Composition comprising a particular oxidation dye precursor and a particular amino silicone | L'ORÉAL (FR) | 2026-02-24 | — | — | US | disclosed |
| EP-3825361-B1 | ORGANOPOLYSILOXANE EMULSION COMPOSITION | SHINETSU CHEMICAL CO (JP) | 2025-11-26 | — | — | EP | disclosed |
| EP-0635265-A1 | Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid | LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) | 1995-01-25 | — | — | EP | disclosed |
| US-4565635-A | GUM, POLYMER, OR BIOGUM MATERIAL AND WATER DONOR MATERIAL MIXTURE | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1986-01-21 | — | — | US | disclosed |
| US-4548734-A | IMPROVED DISPERSABILITY | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-10-22 | — | — | US | disclosed |
| US-4308148-A | Preparation of water soluble polymeric flocculants by photopolymerization of hydrophilic monomers | RHONE-POULENC INDUSTRIES (FR) | 1981-12-29 | — | — | US | disclosed |
| US-4306955-A | Photopolymerized acrylic polymer essentially devoid of residual monomer(s) | RHONE-POULENC INDUSTRIES (FR) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558301-B2 | Composition comprising a particular oxidation dye precursor and a particular amino silicone | KRT18, PLOD1, PLOD2 | HRH1 3000/4885CA4 1590/4885BBOX1 1333/4885 |
| US-12622853-B2 | Composition comprising a particular oxidation dye precursor and a particular amino silicone | KRT18, SCNN1B, PLOD3 | HRH1 159/4885CA4 856/4885BBOX1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.